Veru Inc. Files 8-K: Material Definitive Agreement
Ticker: VERU · Form: 8-K · Filed: Apr 26, 2024 · CIK: 863894
Sentiment: neutral
Topics: material-definitive-agreement, corporate-filing
TL;DR
Veru Inc. signed a big deal on 4/24/24. Details to follow.
AI Summary
Veru Inc. entered into a Material Definitive Agreement on April 24, 2024. The company, previously known as FEMALE HEALTH CO and WISCONSIN PHARMACAL COMPANY INC, is incorporated in Wisconsin and headquartered in Miami, Florida. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a significant new agreement for Veru Inc., which could impact its business operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial 8-K filing.
Key Numbers
- 001-13602 — SEC File Number (Identifies the company's filing history with the SEC.)
- 39-1144397 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Veru Inc. (company) — Registrant
- FEMALE HEALTH CO (company) — Former company name
- WISCONSIN PHARMACAL COMPANY INC (company) — Former company name
- April 24, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on April 24, 2024.
What is Veru Inc.'s primary business?
Veru Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When was Veru Inc. incorporated?
Veru Inc. was incorporated in Wisconsin.
What is Veru Inc.'s principal executive office address?
The principal executive offices are located at 2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127.
What is the company's fiscal year end?
Veru Inc.'s fiscal year ends on September 30.
Filing Stats: 955 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-04-26 16:27:59
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share VERU NASDAQ Cap
- $5,000,000 — missory Note in the principal amount of $5,000,000 due on April 19, 2024 (the "April 2024
- $50,000 — he Borrower agreed to make a payment of $50,000 of the principal payable under the Apri
Filing Documents
- d799173d8k.htm (8-K) — 29KB
- d799173dex101.htm (EX-10.1) — 30KB
- 0001193125-24-118157.txt ( ) — 188KB
- veru-20240424.xsd (EX-101.SCH) — 3KB
- veru-20240424_lab.xml (EX-101.LAB) — 18KB
- veru-20240424_pre.xml (EX-101.PRE) — 11KB
- d799173d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Document 10.1 Forbearance Agreement, dated as of April 24, 2024, between Veru Inc. and Onconetix, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 26, 2024 VERU INC. By: /s/ Michele Greco Michele Greco Chief Financial Officer and Chief Administrative Officer 3